Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BMY Stock Summary
Top 10 Correlated ETFs
BMY
In the News
Bristol Myers' bowel disease drug fails to meet main goal in late-stage study
Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, failed to meet the main goal in a late-stage study.
Is Bristol Myers Squibb Stock a Buy?
Bristol Myers is already facing a major patent cliff, but there are more on the horizon. The company is developing and launching important new medicines to replace older ones.
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.59, marking a -0.56% move from the previous day.
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
Bristol Myers liver cancer treatment meets main goal of late-stage study
Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as a first-line treatment for a type of liver cancer.
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy
Advisers to the U.S. Food and Drug Administration on Friday voted in favor of allowing the use of Bristol Myers Squibb's cell therapy as an earlier treatment for a type of blood cancer.
BMY Financial details
BMY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 15.33 | 18.83 | 20.88 | 21.52 | 21.75 | |
Net income per share | 2.02 | -3.98 | 3.15 | 2.95 | 3.88 | |
Operating cash flow per share | 4.73 | 6.22 | 7.3 | 6.09 | 6.7 | |
Free cash flow per share | 4.24 | 5.89 | 6.86 | 5.57 | 6.11 | |
Cash per share | 9.03 | 7.01 | 7.75 | 4.31 | 5.94 | |
Book value per share | 30.26 | 16.75 | 16.18 | 14.48 | 14.22 | |
Tangible book value per share | -20.39 | -15.9 | -12.28 | -12.3 | -9.26 | |
Share holders equity per share | 30.26 | 16.75 | 16.18 | 14.48 | 14.22 | |
Interest debt per share | 28.27 | 23.51 | 21.13 | 19.56 | 20.6 | |
Market cap | 109.44B | 140.06B | 138.48B | 154.31B | 106.16B | |
Enterprise value | 144.64B | 177.19B | 170.1B | 185.91B | 136.16B | |
P/E ratio | 31.82 | -15.57 | 19.8 | 24.39 | 13.23 | |
Price to sales ratio | 4.19 | 3.29 | 2.99 | 3.34 | 2.36 | |
POCF ratio | 13.57 | 9.97 | 8.54 | 11.81 | 7.66 | |
PFCF ratio | 15.14 | 10.53 | 9.09 | 12.92 | 8.39 | |
P/B Ratio | 2.12 | 3.7 | 3.85 | 4.97 | 3.61 | |
PTB ratio | 2.12 | 3.7 | 3.85 | 4.97 | 3.61 | |
EV to sales | 5.53 | 4.17 | 3.67 | 4.03 | 3.03 | |
Enterprise value over EBITDA | 21.92 | 11.96 | 8.43 | 9.33 | 7.1 | |
EV to operating cash flow | 17.93 | 12.61 | 10.5 | 14.23 | 9.82 | |
EV to free cash flow | 20 | 13.32 | 11.17 | 15.56 | 10.76 | |
Earnings yield | 0.03 | -0.06 | 0.05 | 0.04 | 0.08 | |
Free cash flow yield | 0.07 | 0.09 | 0.11 | 0.08 | 0.12 | |
Debt to equity | 0.92 | 1.37 | 1.27 | 1.31 | 1.41 | |
Debt to assets | 0.37 | 0.44 | 0.42 | 0.42 | 0.44 | |
Net debt to EBITDA | 5.33 | 2.51 | 1.57 | 1.59 | 1.56 | |
Current ratio | 1.6 | 1.58 | 1.52 | 1.25 | 1.43 | |
Interest coverage | 8.33 | 3.61 | 7.62 | 8.38 | 14.79 | |
Income quality | 2.33 | -1.56 | 2.31 | 2.06 | 1.72 | |
Dividend Yield | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | |
Payout ratio | 0.78 | -0.45 | 0.63 | 0.73 | 0.59 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.24 | 0.26 | 0.22 | 0.21 | 0.21 | |
Intangibles to total assets | 0.67 | 0.62 | 0.58 | 0.59 | 0.51 | |
Capex to operating cash flow | -0.1 | -0.05 | -0.06 | -0.09 | -0.09 | |
Capex to revenue | -0.03 | -0.02 | -0.02 | -0.02 | -0.03 | |
Capex to depreciation | -0.48 | -0.07 | -0.09 | -0.11 | -0.12 | |
Stock based compensation to revenue | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
Graham number | 37.06 | 38.75 | 33.86 | 31 | 35.23 | |
ROIC | 0.04 | 0.07 | 0.11 | 0.12 | 0.23 | |
Return on tangible assets | 0.08 | -0.2 | 0.15 | 0.16 | 0.17 | |
Graham Net | -32.22 | -25.4 | -20.55 | -20.9 | -19.63 | |
Working capital | 11.05B | 11.11B | 11.39B | 5.38B | 9.51B | |
Tangible asset value | -34.76B | -35.91B | -27.27B | -26.39B | -19.17B | |
Net current asset value | -48.89B | -50.41B | -40.05B | -38.43B | -33.9B | |
Invested capital | 0.92 | 1.37 | 1.27 | 1.31 | 1.41 | |
Average receivables | 6.83B | 8.09B | 10.51B | 13.23B | 14.6B | |
Average payables | 2.17B | 2.58B | 2.83B | 2.99B | 3.15B | |
Average inventory | 2.74B | 3.18B | 2.08B | 2.22B | 2.5B | |
Days sales outstanding | 107.29 | 72.98 | 98.49 | 110.21 | 123.79 | |
Days payables outstanding | 110.48 | 84.11 | 108.29 | 109.46 | 111.24 | |
Days of inventory on hand | 193.98 | 64.3 | 76.93 | 84.22 | 90.87 | |
Receivables turnover | 3.4 | 5 | 3.71 | 3.31 | 2.95 | |
Payables turnover | 3.3 | 4.34 | 3.37 | 3.33 | 3.28 | |
Inventory turnover | 1.88 | 5.68 | 4.74 | 4.33 | 4.02 | |
ROE | 0.07 | -0.24 | 0.19 | 0.2 | 0.27 | |
Capex per share | -0.49 | -0.33 | -0.44 | -0.52 | -0.58 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 5.41 | 5.4 | 5.36 | 5.33 | 5.66 | |
Net income per share | 0.96 | 1.08 | 0.99 | 0.94 | 0.87 | |
Operating cash flow per share | 1.57 | 1.41 | 0.9 | 2.31 | 2.1 | |
Free cash flow per share | 1.4 | 1.28 | 0.78 | 2.14 | 1.93 | |
Cash per share | 4.39 | 4.42 | 4.17 | 3.74 | 6.06 | |
Book value per share | 14.73 | 15.16 | 15.28 | 14.1 | 14.52 | |
Tangible book value per share | -12.52 | -11.11 | -9.99 | -10.43 | -9.46 | |
Share holders equity per share | 14.73 | 15.16 | 15.28 | 14.1 | 14.52 | |
Interest debt per share | 19.45 | 18.89 | 18.86 | 19.23 | 20.61 | |
Market cap | 151.67B | 145.48B | 133.85B | 119.39B | 104.01B | |
Enterprise value | 183.26B | 175.86B | 164.66B | 151.14B | 134.01B | |
P/E ratio | 18.75 | 16.08 | 16.14 | 15.48 | 14.76 | |
Price to sales ratio | 13.3 | 12.83 | 11.92 | 10.89 | 9.06 | |
POCF ratio | 45.88 | 48.98 | 70.93 | 25.13 | 24.46 | |
PFCF ratio | 51.24 | 54.04 | 82.22 | 27.08 | 26.52 | |
P/B Ratio | 4.88 | 4.57 | 4.19 | 4.12 | 3.53 | |
PTB ratio | 4.88 | 4.57 | 4.19 | 4.12 | 3.53 | |
EV to sales | 16.07 | 15.51 | 14.67 | 13.78 | 11.68 | |
Enterprise value over EBITDA | 38.88 | 34.51 | 35.59 | 35.86 | 32.31 | |
EV to operating cash flow | 55.43 | 59.21 | 87.26 | 31.81 | 31.52 | |
EV to free cash flow | 61.91 | 65.33 | 101.14 | 34.28 | 34.17 | |
Earnings yield | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
Free cash flow yield | 0.02 | 0.02 | 0.01 | 0.04 | 0.04 | |
Debt to equity | 1.31 | 1.24 | 1.23 | 1.35 | 1.41 | |
Debt to assets | 0.42 | 0.42 | 0.42 | 0.43 | 0.44 | |
Net debt to EBITDA | 6.7 | 5.96 | 6.66 | 7.53 | 7.23 | |
Current ratio | 1.25 | 1.42 | 1.39 | 1.18 | 1.43 | |
Interest coverage | 8.06 | 9.86 | 14.74 | 15.05 | 5.33 | |
Income quality | 1.63 | 1.31 | 0.91 | 2.46 | 2.41 | |
Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Payout ratio | 0.57 | 0.53 | 0.58 | 0.62 | 0.66 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.22 | 0.2 | 0.2 | 0.2 | 0.22 | |
Intangibles to total assets | 0.59 | 0.59 | 0.57 | 0.55 | 0.51 | |
Capex to operating cash flow | -0.1 | -0.09 | -0.14 | -0.07 | -0.08 | |
Capex to revenue | -0.03 | -0.02 | -0.02 | -0.03 | -0.03 | |
Capex to depreciation | -0.14 | -0.11 | -0.11 | -0.14 | -0.13 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 17.83 | 19.17 | 18.45 | 17.24 | 16.85 | |
ROIC | 0.04 | 0.03 | 0.06 | 0.05 | 0.02 | |
Return on tangible assets | 0.05 | 0.06 | 0.05 | 0.05 | 0.04 | |
Graham Net | -21.27 | -19.9 | -19.23 | -20.21 | -20.04 | |
Working capital | 5.38B | 8B | 7.92B | 4.17B | 9.51B | |
Tangible asset value | -26.39B | -23.33B | -20.91B | -21.46B | -19.17B | |
Net current asset value | -38.43B | -35.31B | -33.39B | -34.57B | -33.9B | |
Invested capital | 1.31 | 1.24 | 1.23 | 1.35 | 1.41 | |
Average receivables | 13.59B | 13.67B | 14.23B | 15.35B | 15.46B | |
Average payables | 2.82B | 3.12B | 3.13B | 2.94B | 3.04B | |
Average inventory | 2.21B | 2.47B | 2.48B | 2.4B | 2.55B | |
Days sales outstanding | 109.97 | 106.42 | 120.73 | 128.42 | 119.7 | |
Days payables outstanding | 105.51 | 112.03 | 96.04 | 101.03 | 106.85 | |
Days of inventory on hand | 81.18 | 91.37 | 73.98 | 87.49 | 87.28 | |
Receivables turnover | 0.82 | 0.85 | 0.75 | 0.7 | 0.75 | |
Payables turnover | 0.85 | 0.8 | 0.94 | 0.89 | 0.84 | |
Inventory turnover | 1.11 | 0.99 | 1.22 | 1.03 | 1.03 | |
ROE | 0.07 | 0.07 | 0.06 | 0.07 | 0.06 | |
Capex per share | -0.16 | -0.13 | -0.12 | -0.17 | -0.16 |
BMY Frequently Asked Questions
What is Bristol-Myers Squibb Company stock symbol ?
Bristol-Myers Squibb Company is a US stock , located in New york of Ny and trading under the symbol BMY
Is Bristol-Myers Squibb Company buy or a sell ?
18 stock analysts have 18 predictions with a medium analyst target price of $73.56. The lowest prediction is $55 and the highest is $92
What is BMY stock prediction ?
With a median analyst target price of $55, 1 stock analysts have made 1 forecasts in last 90 days. $55 is the lowest and $55 is the greatest projection.
What is Bristol-Myers Squibb Company stock quote today ?
Bristol-Myers Squibb Company stock price is $54.23 today.
Is Bristol-Myers Squibb Company stock public?
Yes, Bristol-Myers Squibb Company is a publicly traded company.